Cingulate Inc. (CING) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cingulate Inc. (CING)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.87

0.25 (5.41%)

At close: Jan 15, 2025, 12:16 PM

undefined% (undefined)

Bid	4.71
Market Cap	15.64M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-43.22
PE Ratio (ttm)	-0.11
Forward PE	n/a
Analyst	Buy

Ask	4.85
Volume	41,558
Avg. Volume (20D)	165,868
Open	4.66
Previous Close	4.62
Day's Range	4.62 - 4.87
52-Week Range	1.80 - 72.00
Beta	undefined

About CING

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety diso...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 8, 2021

Employees 13

Stock Exchange NASDAQ

Ticker Symbol CING

Website https://www.cingulate.com

Analyst Forecast

According to 2 analyst ratings, the average rating for CING stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 146.41% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

+9.27%

Cingulate shares are trading higher after Maxim Gr... Unlock content with Pro Subscription

4 months ago · Source

-8.76%

Cingulate shares are trading lower. The company announced it commenced its final FDA-required study, which is a food effect study, for CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder.

News

5 months ago · invezz.com

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Inc (NASDAQ: CING), a biopharmaceutical firm specializing in innovative ADHD treatments, experienced a remarkable surge in its stock price on Friday, with shares skyrocketing by 115%. This d...

5 months ago · benzinga.com

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

1 year ago · investorplace.com

Why Is Cingulate (CING) Stock Up 160% Today?

Cingulate (NASDAQ: CING ) stock is soaring over 160% in early trading and trending on many financial news websites. The rally was sparked by the company's announcement that the Nasdaq exchange would p...

1 year ago · marketwatch.com

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Shares of Cingulate Inc. CING, +101.52% blasted 226.3% higher in premarket trading Thursday after the biopharmaceutical company disclosed that the delisting of its stock has been delayed until at leas...

1 year ago · newsfilecorp.com

Cingulate Inc. To Present at the LD Micro Main Event XVI

Presentation on Wednesday, October 4th at 02:30 PM PT Kansas City, Kansas--(Newsfile Corp. - September 21, 2023) - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary ...

1 year ago · pennystocks.com

Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch

Short squeeze penny stocks to watch. The post Best Penny Stocks To Buy?

1 year ago · pennystocks.com

Building a Penny Stocks Portfolio For Long Term

Use these tips for buying penny stocks for the long term The post Building a Penny Stocks Portfolio For Long Term appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

1 year ago · pennystocks.com

The Psychology of Penny Stock Trading: Tips for Emotional Control

Tips for making money with penny stocks The post The Psychology of Penny Stock Trading: Tips for Emotional Control appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

1 year ago · investorplace.com

Why Is Cingulate (CING) Stock Up 72% Today?

Cingulate (NASDAQ: CING ) stock is on the rise Friday after releasing positive data concerning its ADHD treatment. The big news today is Cingulate's CTx-1301 can be taken with or without food.

1 year ago · marketwatch.com

Cingulate stock skyrockets after ADHD treatment shows positive trial results

Shares of Cingulate Inc. CING, +2.78% skyrocketed 82.9% toward an 11-month high in active premarket trading Friday, after the biopharmaceutical company reported positive results from a trial of its at...

2 years ago · newsfilecorp.com

Cingulate Inc. to Present at Investor Summit Group's Q4 Conference

Kansas City, Kansas--(Newsfile Corp. - November 3, 2022) - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform t...

2 years ago · benzinga.com

Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder Studies

Cingulate Inc CING plans to initiate Phase 3 studies for CTx-1301 for Attention Deficit/Hyperactivity Disorder (ADHD) in 2022. Get the Inside Access Traders Are Using to Profit More and Win Bigger.